½ÃÀ庸°í¼­
»óǰÄÚµå
1408964

¼¼°èÀÇ ¸¶ÀÌÅ©·Î RNA ½ÃÀå : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2032³â)

Global MicroRNA Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 235 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¸¶ÀÌÅ©·Î RNA ½ÃÀå ±Ô¸ð´Â 2023³â 24¾ï 5,000¸¸ ´Þ·¯¿¡¼­ 2032³â¿¡´Â 74¾ï 9,000¸¸ ´Þ·¯ ±Ùó¿¡ ´ÞÇϸç, Á¶»ç ±â°£ÀÎ 2024-2032³â CAGRÀº 13.24%·Î ÃßÁ¤µË´Ï´Ù.

¸¶ÀÌÅ©·ÎRNA(miRNA)´Â ÀϹÝÀûÀ¸·Î ¾à 20-22°³ÀÇ ´ºÅ¬·¹¿ÀƼµå·Î ±¸¼ºµÈ ºñ¾Ïȣȭ RNA ºÐÀÚ·Î, ƯÁ¤ ¸Þ½ÅÀú RNA(mRNA) ºÐÀÚ¿¡ °áÇÕÇÏ¿© ±× ¾ÈÁ¤¼º°ú ´Ü¹éÁú·ÎÀÇ ¹ø¿ª¿¡ ¿µÇâÀ» ¹ÌÃÄ ±â´ÉÇÕ´Ï´Ù. ÀÌ ÂªÀº RNA ¼­¿­Àº À¯ÀüÀÚ ¹ßÇöÀ» Á¶ÀýÇÏ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù.

½ÃÀå ¿ªÇÐ

¸¶ÀÌÅ©·ÎRNA ½ÃÀåÀº À¯ÀüÀÚ Á¶Àý¿¡¼­ ¸¶ÀÌÅ©·ÎRNAÀÇ º¹ÀâÇÑ ¿ªÇÒ¿¡ ÃÊÁ¡À» ¸ÂÃá ºÐÀÚ»ý¹°ÇÐ ¿¬±¸ÀÇ È®´ë¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Áúº´, ƯÈ÷ ¾Ï°ú ½ÉÇ÷°ü ÁúȯÀÇ ±ÍÁßÇÑ ¹ÙÀÌ¿À¸¶Ä¿·Î¼­ ¸¶ÀÌÅ©·Î RNA¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¿¬±¸¿Í Áø´Ü¿¡ ÅëÇյǰí ÀÖ½À´Ï´Ù. ½ÃÄö½Ì ±â¼úÀÇ ¹ßÀüÀ¸·Î ¸¶ÀÌÅ©·Î RNA ¹ßÇö ÇÁ·ÎÆÄÀÏÀÇ ³ôÀº 󸮷® ºÐ¼®ÀÌ °¡´ÉÇØÁö¸é¼­ ¿¬±¸ ¹× ÀÓ»ó Àû¿ë¿¡ ´ëÇÑ µµÀÔÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ¸¶ÀÌÅ©·Î RNAÀÇ Áø´Ü ¹× Ä¡·á °¡´É¼º¿¡ ÈûÀÔ¾î ½ÃÀåÀº ÀǾàǰ °³¹ß, Ç¥Àû Ž»ö ¹× ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ Å½±¸¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÇöÀç ÁøÇà ÁßÀÎ ¾Ï ¿¬±¸´Â Á¾¾çÇп¡¼­ ¸¶ÀÌÅ©·Î RNAÀÇ Á߿伺À» °­Á¶ÇÏ¸ç ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Á¤ºÎÀÇ ÀÚ±Ý Áö¿ø, °øµ¿ ±¸»ó, °ËÃâ ¹æ¹ýÀÇ ±â¼ú Çõ½ÅÀº ¸¶ÀÌÅ©·Î RNA ¿¬±¸ ÅøÀÇ ´É·Â°ú µµ´Þ ¹üÀ§¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯÀÇ ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Áúº´ ¹ß»ý¿¡ ÀÖÀ¸¸ç, ¸¶ÀÌÅ©·Î RNAÀÇ ¿ªÇÒ¿¡ ´ëÇÑ ÀÌÇØ¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϸ鼭 ¸¶ÀÌÅ©·Î RNA ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ß°¡ °è¼Ó ¹ßÀüÇÔ¿¡ µû¶ó ¸¶ÀÌÅ©·Î RNA ¿¬±¸´Â ´Ù¾çÇÑ ÀÇ·á ¿ëµµ¿¡¼­ Áø´Ü ¹× Ä¡·á¹ýÀ» ¹ßÀü½Ãų ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

ÀÌ Á¶»ç ¸®Æ÷Æ®´Â Porter's Five Forces ¸ðµ¨, ½ÃÀåÀÇ ¸Å·Â ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ç°í ÀÖ½À´Ï´Ù. ÀÌ ÅøÀº ¾÷°èÀÇ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇϰí, ¼¼°è ·¹º§¿¡¼­ÀÇ °æÀï ¸Å·ÂÀ» Æò°¡Çϴµ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ ÅøÀº ¼¼°èÀÇ ¸¶ÀÌÅ©·Î RNA ½ÃÀå¿¡¼­ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼öµµ ÀÖ½À´Ï´Ù. ¸¶ÀÌÅ©·Î RNA »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ Á¶»ç¿¡ ÀüüÀûÀÎ ¾îÇÁ·ÎÄ¡¸¦ Á¦°øÇÕ´Ï´Ù.

Áö¿ª ºÐ¼®

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡¼­ ¸¶ÀÌÅ©·Î RNA ½ÃÀå ÇöÀ硤ÇâÈÄ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ç°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¸ðµç ÁÖ¿ä Áö¿ª¿¡¼­ °³º° ¿ëµµ ºÎ¹®ÀÇ ¼ö¿ä¡¤ÃßÁ¤¡¤¿¹Ãø¿¡µµ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.

¸ÂÃãÇü ¿ä±¸»çÇ×ÀÌ ÀÖ´Â °æ¿ì, ¹®ÀÇÇØÁֽñ⠹ٶø´Ï´Ù. ¸®¼­Ä¡ÆÀÀÌ °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼­¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀåÀÇ ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ½º³À¼ô

Á¦3Àå ¸¶ÀÌÅ©·Î RNA-»ê¾÷ ºÐ¼®

  • ¼­·Ð : ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • ¾÷°è µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷üÀÇ ¸®½ºÆ®
    • ÁÖ¿ä ¿øÀç·áÀÇ °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
  • ¸¶ÄÉÆÃ Ã¤³Î
    • ´ÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
    • ÀδÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ¸¶ÀÌÅ©·Î RNA ½ÃÀå ºÐ¼® : Á¦Ç°¡¤¼­ºñ½ºº°

  • Á¦Ç°¡¤¼­ºñ½ºº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • Á¦Ç°¡¤¼­ºñ½ºº° ºÐ¼®
  • ¼­ºñ½º(À¯Çü, °Ëü)
  • Á¦Ç°(±â±â, ¿öÅ©Ç÷οì, ¼Ò¸ðǰ, ÀüÇ÷)

Á¦6Àå ¼¼°èÀÇ ¸¶ÀÌÅ©·Î RNA ½ÃÀå ºÐ¼® : ¿ëµµº°

  • ¿ëµµº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ¿ëµµº° ºÐ¼®
  • ¾Ï
  • °¨¿°Áõ
  • ¸é¿ªÁúȯ
  • ½ÉÇ÷°üÁúȯ
  • ½Å°æÁúȯ
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ ¸¶ÀÌÅ©·Î RNA ½ÃÀå ºÐ¼® : ÃÖÁ¾ ¿ëµµº°

  • ÃÖÁ¾ ¿ëµµº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ÃÖÁ¾ ¿ëµµº° ºÐ¼®
  • ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¡¤Á¦¾à±â¾÷
  • Çмú¡¤Á¤ºÎ ¿¬±¸±â°ü
  • ±âŸ

Á¦8Àå ¼¼°èÀÇ ¸¶ÀÌÅ©·Î RNA ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼­·Ð
  • ºÏ¹ÌÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä¡¤½ÇÀû¡¤¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä¡¤½ÇÀû¡¤¿¹Ãø
    • À¯·´ : ºÎ¹®º°
    • À¯·´ : ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä¡¤½ÇÀû¡¤¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä« ÆÇ¸Å ºÐ¼®
    • °³¿ä¡¤½ÇÀû¡¤¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä¡¤½ÇÀû¡¤¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º°
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ¸¶ÀÌÅ©·Î RNA ±â¾÷ÀÇ °æÀï ±¸µµ

  • ¸¶ÀÌÅ©·Î RNA ½ÃÀåÀÇ °æÀï
  • Á¦ÈÞ¡¤Çù¾÷¡¤ÇùÁ¤
  • ÇÕº´¡¤Àμö
  • ½ÅÁ¦Ç° Ãâ½Ã
  • ±âŸ °³¹ß

Á¦10Àå ±â¾÷ °³¿ä

  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • Thermo Fisher Scientific Inc.
  • QIAGEN
  • Horizon Discovery Group plc
  • NanoString Technologies Inc.
  • Merck KGaA
  • Takara Bio Inc
  • LGC Limited
  • BioGenex
  • GeneCopoeia Inc
  • New England Biolabs
KSA 24.01.25

The global demand for MicroRNA Market is presumed to reach the market size of nearly USD 7.49 BN by 2032 from USD 2.45 BN in 2023 with a CAGR of 13.24% under the study period 2024 - 2032.

MicroRNA (miRNA) are non-coding RNA molecules typically consisting of about 20-22 nucleotides that function by binding to specific messenger RNA (mRNA) molecules, thereby influencing their stability and translation into proteins. These short RNA sequences assist in the regulation of gene expression.

MARKET DYNAMICS

The microRNA market is driven by the expanding landscape of molecular biology research, with a focus on the intricate role of microRNAs in gene regulation. Increasing awareness of microRNAs as valuable biomarkers for diseases, particularly in cancer and cardiovascular disorders, contributes to their integration into research and diagnostics. Advancements in sequencing technologies enable high-throughput analysis of microRNA expression profiles, fostering adoption in research and clinical applications. The market is propelled by the diagnostic and therapeutic potential of microRNAs, prompting exploration in drug development, target discovery, and personalized medicine. Ongoing cancer research emphasizes the significance of microRNAs in oncology, further fueling market growth. Government funding, collaborative initiatives, and technological innovations in detection methods enhance the capabilities and reach of microRNA research tools. With the rising incidence of chronic diseases, there is an increased demand for understanding the role of microRNAs in disease pathogenesis, driving the expansion of the microRNA market. As the field continues to evolve, microRNA research holds promise for advancing diagnostics and therapeutics across diverse medical applications.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of microrna. The growth and trends of microrna industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the microrna market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Products & Services

  • Services (Type, Specimen)
  • Products (Instruments, Workflow, Consumables, Whole Blood)

By Application

  • Cancer
  • Infectious Diseases
  • Immunological Disorder
  • Cardiovascular Disease
  • Neurological Disease
  • Others

By End-Use

  • Biotechnology & Pharmaceutical Companies
  • Academic & Government Research Institutes
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the MicroRNA market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the MicroRNA market include Thermo Fisher Scientific Inc., QIAGEN, Horizon Discovery Group plc, NanoString Technologies, Inc., Merck KGaA, Takara Bio Inc, LGC Limited, BioGenex, GeneCopoeia Inc, New England Biolabs. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . MICRORNA - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Products & Services
    • 3.7.2 Market Attractiveness Analysis By Application
    • 3.7.3 Market Attractiveness Analysis By End-use
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL MICRORNA MARKET ANALYSIS BY PRODUCTS & SERVICES

  • 5.1 Overview by Products & Services
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Products & Services
  • 5.4 Services (Type, Specimen) Historic and Forecast Sales by Regions
  • 5.5 Products (Instruments, Workflow, Consumables, Whole Blood) Historic and Forecast Sales by Regions

6 . GLOBAL MICRORNA MARKET ANALYSIS BY APPLICATION

  • 6.1 Overview by Application
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Application
  • 6.4 Cancer Historic and Forecast Sales by Regions
  • 6.5 Infectious Diseases Historic and Forecast Sales by Regions
  • 6.6 Immunological Disorder Historic and Forecast Sales by Regions
  • 6.7 Cardiovascular Disease Historic and Forecast Sales by Regions
  • 6.8 Neurological Disease Historic and Forecast Sales by Regions
  • 6.9 Others Historic and Forecast Sales by Regions

7 . GLOBAL MICRORNA MARKET ANALYSIS BY END-USE

  • 7.1 Overview by End-use
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by End-use
  • 7.4 Biotechnology & Pharmaceutical Companies Historic and Forecast Sales by Regions
  • 7.5 Academic & Government Research Institutes Historic and Forecast Sales by Regions
  • 7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL MICRORNA MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2. North America By Segment Sales Analysis
    • 8.3.3. North America By Country Sales Analysis
    • 8.3.4. United State Sales Analysis
    • 8.3.5. Canada Sales Analysis
    • 8.3.6. Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2. Europe by Segment Sales Analysis
    • 8.4.3. Europe by Country Sales Analysis
    • 8.4.4. United Kingdom Sales Analysis
    • 8.4.5. France Sales Analysis
    • 8.4.6. Germany Sales Analysis
    • 8.4.7. Italy Sales Analysis
    • 8.4.8. Russia Sales Analysis
    • 8.4.9. Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2. Asia Pacific by Segment Sales Analysis
    • 8.5.3. Asia Pacific by Country Sales Analysis
    • 8.5.4. China Sales Analysis
    • 8.5.5. India Sales Analysis
    • 8.5.6. Japan Sales Analysis
    • 8.5.7. South Korea Sales Analysis
    • 8.5.8. Australia Sales Analysis
    • 8.5.9. South East Asia Sales Analysis
    • 8.5.10. Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2. Latin America by Segment Sales Analysis
    • 8.6.3. Latin America by Country Sales Analysis
    • 8.6.4. Brazil Sales Analysis
    • 8.6.5. Argentina Sales Analysis
    • 8.6.6. Peru Sales Analysis
    • 8.6.7. Chile Sales Analysis
    • 8.6.8. Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2. Middle East & Africa by Segment Sales Analysis
    • 8.7.3. Middle East & Africa by Country Sales Analysis
    • 8.7.4. Saudi Arabia Sales Analysis
    • 8.7.5. UAE Sales Analysis
    • 8.7.6. Israel Sales Analysis
    • 8.7.7. South Africa Sales Analysis
    • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE MICRORNA COMPANIES

  • 9.1. Microrna Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10 . COMPANY PROFILES OF MICRORNA INDUSTRY

  • 10.1. Company Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Thermo Fisher Scientific Inc.
    • 10.3.1. Company Overview
    • 10.3.2. Company Revenue
    • 10.3.3. Products
    • 10.3.4. Recent Developments
  • 10.4. QIAGEN
    • 10.4.1. Company Overview
    • 10.4.2. Company Revenue
    • 10.4.3. Products
    • 10.4.4. Recent Developments
  • 10.5. Horizon Discovery Group plc
    • 10.5.1. Company Overview
    • 10.5.2. Company Revenue
    • 10.5.3. Products
    • 10.5.4. Recent Developments
  • 10.6. NanoString Technologies Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Company Revenue
    • 10.6.3. Products
    • 10.6.4. Recent Developments
  • 10.7. Merck KGaA
    • 10.7.1. Company Overview
    • 10.7.2. Company Revenue
    • 10.7.3. Products
    • 10.7.4. Recent Developments
  • 10.8. Takara Bio Inc
    • 10.8.1. Company Overview
    • 10.8.2. Company Revenue
    • 10.8.3. Products
    • 10.8.4. Recent Developments
  • 10.9. LGC Limited
    • 10.9.1. Company Overview
    • 10.9.2. Company Revenue
    • 10.9.3. Products
    • 10.9.4. Recent Developments
  • 10.10. BioGenex
    • 10.10.1. Company Overview
    • 10.10.2. Company Revenue
    • 10.10.3. Products
    • 10.10.4. Recent Developments
  • 10.11. GeneCopoeia Inc
    • 10.11.1. Company Overview
    • 10.11.2. Company Revenue
    • 10.11.3. Products
    • 10.11.4. Recent Developments
  • 10.12. New England Biolabs
    • 10.12.1. Company Overview
    • 10.12.2. Company Revenue
    • 10.12.3. Products
    • 10.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦